ATE446761T1 - Behandlung und verhütung von gewebeschäden, die mit erhöhter produktion von c-reactivem protein verbunden sind - Google Patents

Behandlung und verhütung von gewebeschäden, die mit erhöhter produktion von c-reactivem protein verbunden sind

Info

Publication number
ATE446761T1
ATE446761T1 AT03727670T AT03727670T ATE446761T1 AT E446761 T1 ATE446761 T1 AT E446761T1 AT 03727670 T AT03727670 T AT 03727670T AT 03727670 T AT03727670 T AT 03727670T AT E446761 T1 ATE446761 T1 AT E446761T1
Authority
AT
Austria
Prior art keywords
reactive protein
prevention
treatment
tissue damage
ligands
Prior art date
Application number
AT03727670T
Other languages
English (en)
Inventor
Mark Pepys
Original Assignee
Pentraxin Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pentraxin Therapeutics Ltd filed Critical Pentraxin Therapeutics Ltd
Application granted granted Critical
Publication of ATE446761T1 publication Critical patent/ATE446761T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
AT03727670T 2002-05-15 2003-05-14 Behandlung und verhütung von gewebeschäden, die mit erhöhter produktion von c-reactivem protein verbunden sind ATE446761T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0211136.7A GB0211136D0 (en) 2002-05-15 2002-05-15 Treatment and prevention of tissue damage
PCT/GB2003/002096 WO2003097104A1 (en) 2002-05-15 2003-05-14 Treatment and prevention of tissue damage

Publications (1)

Publication Number Publication Date
ATE446761T1 true ATE446761T1 (de) 2009-11-15

Family

ID=9936726

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03727670T ATE446761T1 (de) 2002-05-15 2003-05-14 Behandlung und verhütung von gewebeschäden, die mit erhöhter produktion von c-reactivem protein verbunden sind

Country Status (11)

Country Link
US (1) US7615543B2 (de)
EP (1) EP1503800B1 (de)
JP (2) JP2005531559A (de)
AT (1) ATE446761T1 (de)
AU (1) AU2003234000B8 (de)
CA (1) CA2485852C (de)
DE (1) DE60329839D1 (de)
DK (1) DK1503800T3 (de)
ES (1) ES2333522T3 (de)
GB (1) GB0211136D0 (de)
WO (1) WO2003097104A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211136D0 (en) * 2002-05-15 2002-06-26 Univ London Treatment and prevention of tissue damage
US8012472B2 (en) 2002-12-23 2011-09-06 William Marsh Rice University Compositions and methods for suppressing fibrocytes
CA2509241C (en) 2002-12-23 2013-07-30 William Marsh Rice University Use of serum amyloid p (sap) and related compositions for the suppression of fibrosis-related diseases
US7763256B2 (en) 2002-12-23 2010-07-27 William Marsh Rice University Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation
GB0313386D0 (en) * 2003-06-10 2003-07-16 Univ London Treatment of disease
US20070265196A1 (en) * 2004-01-21 2007-11-15 Medvet Science Pty., Ltd. Method of Modulating Pro-Inflammatory and Inflammatory Activity Mediated by C-Reactive Protein
EP1582527A1 (de) * 2004-03-31 2005-10-05 Ciba SC Holding AG Synthese von phosphorbasierenden Liganden
EP1893227A2 (de) 2005-06-06 2008-03-05 Girish J. Kotwal Verfahren zur behandlung oder prophylaxe von atherosklerose und reperfusionsschäden
CA2708004C (en) 2006-12-04 2015-12-01 Promedior, Inc. Conjoint therapy for treating fibrotic diseases
US8497243B2 (en) 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
DK2405928T3 (en) 2009-03-11 2017-01-30 Promedior Inc Treatment and diagnosis procedure for hypersensitive diseases
WO2010104961A1 (en) 2009-03-11 2010-09-16 Promedior, Inc. Treatment methods for autoimmune disorders
UA110323C2 (en) 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
US8329659B2 (en) 2009-06-17 2012-12-11 Promedior, Inc. SAP variants and their use
US8674027B2 (en) 2009-09-18 2014-03-18 Dow Global Technologies Llc Powdered thermoplastic polyolefin elastomer composition for slush molding processes
EP2580278B1 (de) 2010-06-08 2014-10-29 Dow Global Technologies LLC Polyolefinelastomerzusammensetzung für kunstlederanwendungen
WO2013090524A1 (en) * 2011-12-14 2013-06-20 The Texas A&M University System Compositions associated with and methods of managing neutrophil movement using serum amyloid p (sap)
WO2014036473A1 (en) 2012-08-31 2014-03-06 Kenji Suzuki Supervised machine learning technique for reduction of radiation dose in computed tomography imaging
EP2957563A1 (de) * 2014-06-19 2015-12-23 Pentracor GmbH Trennmaterial mit Phosphorylcholinderivaten
GB202002299D0 (en) 2020-02-19 2020-04-01 Pentraxin Therapeutics Ltd Agents for use in the treatment of tissue damage
WO2021197371A1 (zh) * 2020-03-31 2021-10-07 南京金斯瑞生物科技有限公司 一种含有刚性连接子的生物偶联物
WO2022178594A1 (en) * 2021-02-25 2022-09-01 Baker Heart and Diabetes Institute C-reactive protein inhibitors
GB202111866D0 (en) 2021-08-18 2021-09-29 Ucl Business Plc Prodrugs for use in the treatment of tissue damage
KR20230060368A (ko) * 2021-10-27 2023-05-04 솔브레인 주식회사 환형 포스핀 화합물의 제조방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4640913A (en) 1983-01-10 1987-02-03 American Cyanamid Company Phosphocholine derivatives having antihypertensive action
IL84252A (en) 1987-10-23 1994-02-27 Yissum Res Dev Co Phospholipase inhibiting compositions
US5811568A (en) 1992-10-08 1998-09-22 Shaman Pharmaceuticals, Inc. Process for the preparation of mono- and bis(phosphocholine) derivatives which have antifungal activity
US5681829A (en) 1992-10-08 1997-10-28 Shaman Pharmaceuticals, Inc. Class of phosphocholine derivatives having antifungal activity
JP4524846B2 (ja) 2000-04-20 2010-08-18 日油株式会社 化粧料
US6764826B2 (en) 2000-06-08 2004-07-20 Board Of Regents, The University Of Texas System Inhibitors of C-reactive protein induced inflammation
US7390795B2 (en) * 2000-12-18 2008-06-24 Pentraxin Therapeutics Limited Treatment and prevention of tissue damage
EP1418905B1 (de) * 2001-08-08 2007-05-02 Pentraxin Therapeutics Limited Wirkstoff zur entfernung einer unerwünschten proteinpopulation aus dem plasma
GB0211136D0 (en) * 2002-05-15 2002-06-26 Univ London Treatment and prevention of tissue damage

Also Published As

Publication number Publication date
AU2003234000B2 (en) 2008-06-05
ES2333522T3 (es) 2010-02-23
JP2010174013A (ja) 2010-08-12
US20060019930A1 (en) 2006-01-26
AU2003234000A1 (en) 2003-12-02
GB0211136D0 (en) 2002-06-26
US7615543B2 (en) 2009-11-10
CA2485852C (en) 2012-01-17
AU2003234000B8 (en) 2008-07-31
DK1503800T3 (da) 2010-02-01
JP2005531559A (ja) 2005-10-20
WO2003097104A1 (en) 2003-11-27
DE60329839D1 (de) 2009-12-10
CA2485852A1 (en) 2003-11-27
EP1503800B1 (de) 2009-10-28
EP1503800A1 (de) 2005-02-09

Similar Documents

Publication Publication Date Title
ATE446761T1 (de) Behandlung und verhütung von gewebeschäden, die mit erhöhter produktion von c-reactivem protein verbunden sind
EA200801172A1 (ru) Лиганды, имеющие специфичность связывания в отношении рецептора эпидермального фактора роста (egfr) и/или сосудистого эндотелиального фактора роста (vegf), и способы их применения
WO2021163064A3 (en) Antibodies and fusion proteins that bind to ccr8 and uses thereof
EA200301117A1 (ru) Антитела против vla-1
ATE515514T1 (de) Verwendungen von säuger-cytokin il-23 ; verwandte reagenzien
EA200602044A1 (ru) Молекулярно впечатанные полимеры, селективные по отношению к нитрозаминам, и способы их применения
WO2007015107A3 (en) Artificial platelets
WO2006020060A3 (en) Iap binding compounds
EA200200105A1 (ru) СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АКТИВНОСТЬ PPARγ;
EA201001734A1 (ru) Улучшенные связывающие молекулы на основе фибронектина и их применение
EP2221317A3 (de) Pegylierte Single-domain-Antikörper (dAb)
ATE423140T1 (de) Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
ATE40555T1 (de) Verfahren zur organischen synthese von oligosacchariden,welche galactosamin- und uronsaeure-motive umfassen, oligosaccharide und ihre biologischen verwendungen.
BRPI0408317A (pt) anticorpos do receptor de igf-i para o tratamento de cáncer
ATE473242T1 (de) Therapeutische mittel welche einen bispezifischen anti-hla class ii invariant chain x anti-pathogen antikörper enthalten
WO2006129843A3 (en) Bispecific capturing molecule
EP3339327A3 (de) Antikörper gegen unlösliches fibrin
ATE417605T1 (de) Proteine die cross-beta-struktur enthaltendes amyloid binden, sowie verfahren zur modulation der cross-beta-struktur, ihrer bildung und der damit zusammenhängenden toxizität
ATE347898T1 (de) Botulinustoxine zur behandlung von priapismus
EP2631248A3 (de) Behandlung von Tumoren unter Verwendung eines spezifischen Anti-L1-Antikörpers
WO2005019270A3 (en) Endotheliase-2 ligands
WO2021231800A3 (en) Anti-hemojuvelin (hjv) antibodies for treating anemia of chronic disease
EA200870058A1 (ru) Композиции, содержащие остеопонтин крупного рогатого скота, для улучшения процесса заживления ран
ATE416684T1 (de) Gerät zum durchstechen und zusammenfügen von gewebe
ATE363214T1 (de) Löslicher natamycin-proteinkomplex

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties